Tradestie Institutional Equity Comparison Engine

RNA vs GOCO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RNA Overall Edge

RNA Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avidity Biosciences, Inc. Common Stock (RNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RNA trades at N/M Forward P/E with -194.8% operating margin (+24.2% YoY revenue) versus GOCO at N/M Forward P/E and -292.0% operating margin (-94.6% YoY). In options structure, RNA sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro) against GOCO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RNA N/M vs GOCO N/M Fwd P/E
Growth & Margin Winner RNA
Op Margin -194.8% vs -292.0% ยท YoY +24.2% vs -94.6%
Momentum & Technical Winner RNA
1Y -90.8% vs -94.8% ยท 52W Pos 0% vs 0%
Options & Structure Winner RNA
UNCLASSIFIED (2nd %ile IV) vs UNCLASSIFIED (N/A IV)
RNA NASDAQ
Avidity Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$6.51
+1.32% 1D
Market Cap $162.0M
1M Return -14.39%
1Y Return -90.8%
Forward P/E N/M
Unified AI Score
47.4 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 61.0 Mom 55.0
GOCO NASDAQ
GoHealth, Inc. Class A Common Stock
Insurance Agents, Brokers & Service
$0.30
+5.14% 1D
Market Cap $8.5M
1M Return -64.69%
1Y Return -94.78%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RNA -90.8% GOCO -94.78% Spread: +6.29 pp (RNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RNA TTM Op. Margin: -194.8% GOCO TTM Op. Margin: -292.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNA vs GOCO. Trailing 12-month operating profitability (RNA -194.8% vs GOCO -292.0%) and valuation multiples (RNA N/M vs GOCO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RNA (7) vs GOCO (0)
Institutional Metric RNA GOCO Criterion Row Winner
Market Capitalization Scale $162.0M $8.5M Larger Scale RNA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +24.2% -94.6% Higher Growth RNA
Operating Margin (TTM) Profitability -194.8% -292.0% Higher Margin RNA
Net Profit Margin Profitability -180.9% -189.7% Higher Margin RNA
Return on Equity (ROE) Capital Efficiency -95.0% -289.9% Higher ROE RNA
52-Week Range Position Momentum 0% ($6โ€“$73) 0% ($0โ€“$7) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 63% Vol 2.15ฮฒ ยท 201% Vol Lower Realized Risk RNA
Unified Institutional Score Composite Signal 47.4 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite RNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RNA vs GOCO Buy Guide
RNA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live RNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GOCO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GOCO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RNA nor GOCO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.